EZH2 Expression Is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast
- 10 January 2006
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (2), 268-273
- https://doi.org/10.1200/jco.2005.01.5180
Abstract
Purpose EZH2 is a member of the polycomb group of genes and important in cell cycle regulation. Increased expression of EZH2 has been associated previously with invasive growth and aggressive clinical behavior in prostate and breast cancer, but the relationship with tumor cell proliferation has not been examined in human tumors. The purpose of this study was to validate previous findings in a population-based setting, also including tumors that have not been studied previously. Patients and Methods In our study of nearly 700 patients, we examined EZH2 expression and its association with tumor cell proliferation and other tumor markers, clinical features, and prognosis in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Results Strong EZH2 expression was associated with increased tumor cell proliferation in all four cancer types. Associations were also found between EZH2 and important clinicopathologic variables. EZH2 expression showed significant prognostic impact in melanoma, prostate, and endometrial carcinoma in univariate survival analyses, and revealed independent prognostic importance in carcinoma of the endometrium and prostate. Conclusion Our findings point at EZH2 as a novel and independent prognostic marker in endometrial cancer, and validate previous findings on prostate and breast cancer. Further, EZH2 expression was associated with features of aggressive cutaneous melanoma. The fact that EZH2 might identify increased tumor cell proliferation and aggressive subgroups in several cancers may be of practical interest because the polycomb group proteins have been suggested as candidates for targeted therapy. EZH2 expression should, therefore, be further examined as a possible predictive factor.Keywords
This publication has 16 references indexed in Scilit:
- A Basal Epithelial Phenotype Is More Frequent in Interval Breast Cancers Compared with Screen Detected TumorsCancer Epidemiology, Biomarkers & Prevention, 2005
- Activated p53 suppresses the histone methyltransferase EZH2 geneOncogene, 2004
- Prognostic Impact of Alterations in P-Cadherin Expression and Related Cell Adhesion Markers in Endometrial CancerJournal of Clinical Oncology, 2004
- Poorly Differentiated Breast Carcinoma is Associated with Increased Expression of the Human Polycomb Group EZH2 GeneNeoplasia, 2003
- EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancerThe EMBO Journal, 2003
- EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cellsProceedings of the National Academy of Sciences of the United States of America, 2003
- The polycomb group protein EZH2 is involved in progression of prostate cancerNature, 2002
- Programming off and on states in chromatin: mechanisms of Polycomb and trithorax group complexesCurrent Opinion in Genetics & Development, 2002
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991